These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 29153305)

  • 21. Remobilization of hematopoietic stem cells with high-dose methotrexate and cytarabine in patients with non-Hodgkin's lymphoma and multiple myeloma after failure to mobilize with chemotherapy and cytokines.
    Park SJ; Yoon DH; Kim S; Lee K; Park JS; Jang S; Park CJ; Chi HS; Park CS; Huh J; Suh C
    Transfusion; 2014 Mar; 54(3):509-15. PubMed ID: 23800093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive factors for a single successful cytapheresis session during the first mobilisation.
    Gac AC; Parienti JJ; Chantepie S; Cheze S; Johnson-Ansah H; Benabed K; Macro M; Lefevre V; Batho A; Fruchart C; Reman O
    Leuk Res; 2014 Sep; 38(9):1020-4. PubMed ID: 25073661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma.
    Graff TM; Singavi AK; Schmidt W; Eastwood D; Drobyski WR; Horowitz M; Palmer J; Pasquini M; Rizzo DJ; Saber W; Hari P; Fenske TS
    Bone Marrow Transplant; 2015 Jul; 50(7):947-53. PubMed ID: 25867651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hematopoietic progenitor cell mobilization using low-dose cyclophosphamide and granulocyte colony-stimulating factor for multiple myeloma.
    Shimura Y; Kuroda J; Uchiyama H; Kawata-Iida E; Tsutsumi Y; Nagoshi H; Mizutani S; Yamamoto-Sugitani M; Matsumoto Y; Kobayashi T; Horiike S; Shimazaki C; Kaneko H; Kobayashi Y; Taniwaki M
    J Clin Apher; 2013 Oct; 28(5):368-73. PubMed ID: 23804501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unsuccessful stem cell remobilization for autologous transplantation is predicted by renal impairment and a stem cell yield ≤ 0.5 X 10(6) CD34+ cells/kg at first mobilization.
    Hill QA; Pearce R; Cook G
    Bone Marrow Transplant; 2012 Oct; 47(10):1372-3. PubMed ID: 22343671
    [No Abstract]   [Full Text] [Related]  

  • 27. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.
    Damon L; Rugo H; Tolaney S; Navarro W; Martin T; Ries C; Case D; Ault K; Linker C
    Biol Blood Marrow Transplant; 2006 Mar; 12(3):316-24. PubMed ID: 16503501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
    Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
    Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma.
    Samaras P; Pfrommer S; Seifert B; Petrausch U; Mischo A; Schmidt A; Schanz U; Nair G; Bargetzi M; Taverna C; Stupp R; Stenner-Liewen F; Renner C
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):74-80. PubMed ID: 25278456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical analysis of peripheral blood stem cell mobilization regimens in autologous transplantation for treating non-Hodgkin's lymphoma].
    Huang SY; Liu L; Hao MW; Yin DD; Wu YL; Chen RA; Li GH; Lui Q; Wang JC; He H; Liang YM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1415-8. PubMed ID: 22169294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R-ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation.
    Xia W; Ma CK; Reid C; Bai L; Wong K; Kerridge I; Ward C; Greenwood M
    J Clin Apher; 2014 Dec; 29(6):322-30. PubMed ID: 24944079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective noninterventional study on peripheral blood stem cell mobilization in patients with relapsed lymphomas.
    van Gorkom G; Finel H; Giebel S; Pohlreich D; Shimoni A; Ringhoffer M; Sucak G; Schaap N; Dreger P; Sureda A; Schouten HC
    J Clin Apher; 2017 Oct; 32(5):295-301. PubMed ID: 27614935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Continuing erythropoietin during peripheral blood stem cell collection in myeloma: can it reduce toxicity of autologous transplants?
    Labonté L; Iqbal T; McDiarmid S; Bence-Bruckler I; Huebsch L; Allan D
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):132-3. PubMed ID: 18158970
    [No Abstract]   [Full Text] [Related]  

  • 34. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.
    Hamadani M; Kochuparambil ST; Osman S; Cumpston A; Leadmon S; Bunner P; Watkins K; Morrison D; Speir E; Deremer D; Kota V; Jillella A; Craig M; Awan F
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1128-35. PubMed ID: 22248715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High intensity regimens with autologous hematopoietic stem cell transplantation as treatment of multiple myeloma.
    Awedan AA
    Ann Transplant; 2002; 7(2):38-43. PubMed ID: 12416471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
    Chen R; Palmer JM; Martin P; Tsai N; Kim Y; Chen BT; Popplewell L; Siddiqi T; Thomas SH; Mott M; Sahebi F; Armenian S; Leonard J; Nademanee A; Forman SJ
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2136-2140. PubMed ID: 26211987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survivorship after Autologous Hematopoietic Cell Transplantation for Lymphoma and Multiple Myeloma: Late Effects and Quality of Life.
    Georges GE; Bar M; Onstad L; Yi JC; Shadman M; Flowers ME; Carpenter PA; Stewart S; Lee SJ; Holmberg LA
    Biol Blood Marrow Transplant; 2020 Feb; 26(2):407-412. PubMed ID: 31605822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective randomized trial of two popular mononuclear cell collection sets for autologous peripheral blood stem cell collection in multiple myeloma.
    Cooling L; Hoffmann S; Herrst M; Muck C; Armelagos H; Davenport R
    Transfusion; 2010 Jan; 50(1):100-19. PubMed ID: 19719472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.
    Lin TL; Wang PN; Kuo MC; Hung YH; Chang H; Tang TC
    J Clin Apher; 2016 Oct; 31(5):423-8. PubMed ID: 26340986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma.
    Bruns I; Steidl U; Kronenwett R; Fenk R; Graef T; Rohr UP; Neumann F; Fischer J; Scheid C; Hübel K; Haas R; Kobbe G
    Transfusion; 2006 Feb; 46(2):180-5. PubMed ID: 16441592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.